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BACKGROUND AND PURPOSE
Opioids may inhibit the 5-HT transporter (SERT) and the noradrenaline transporter (NET). NET inhibition may contribute to an-
algesia, and SERT inhibition or interactions with 5-HT receptors may cause serotonergic toxicity. However, the effects of different
opioids on the human SERT, NET and 5-HT receptors have not been sufﬁciently studied.
EXPERIMENTAL APPROACH
We determined the potencies of different opioids to inhibit the SERT and NET in vitro using human transporter-transfected
HEK293 cells. We also tested binding afﬁnities at 5-HT1A, 5-HT2A and 5-HT2C receptors. Additionally, we assessed clinical cases of
the serotonin syndrome associated with each opioid reported by PubMed and a World Health Organization database.
KEY RESULTS
Dextromethorphan, l(R)-methadone, racemic methadone, pethidine, tramadol and tapentadol inhibited the SERT at or close to
observed drug plasma or estimated brain concentrations in patients. Tapentadol was the most potent NET inhibitor. Pethidine,
tramadol, l(R)-methadone, racemic methadone, dextromethorphan and O-desmethyltramadol also inhibited the NET. 6-
Monoacetylmorphine, buprenorphine, codeine, dihydrocodeine, heroin, hydrocodone, hydromorphone, morphine, oxycodone
and oxymorphone did not inhibit the SERT or NET. Fentanyl interacted with 5-HT1A receptors and methadone, pethidine and
fentanyl with 5-HT2A receptors, in the lowmicromolar range. Opioids most frequently associated with the serotonin syndrome are
tramadol, fentanyl, tapentadol, oxycodone, methadone and dextromethorphan.
CONCLUSIONS AND IMPLICATIONS
Some synthetic opioids interact with the SERT and NET at potentially clinically relevant concentrations. SERT inhibition by
tramadol, tapentadol, methadone, dextromethorphan and pethidine may contribute to the serotonin syndrome. Direct effects
on 5-HT1A and/or 5-HT2A receptors could be involved with methadone and pethidine.
Abbreviations
DAT, dopamine transporter; ICSR, Individual Case Safety Report; MDMA, 3,4-methylenedioxymethamphetamine; NET,
noradrenaline transporter; SERT, 5-HT transporter
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Introduction
Opioids primarily activate opioid receptors, but some
atypical synthetic opioids have also been shown to interact
with the noradrenaline transporter (NET) and/or the
5-HT (serotonin) transporter (SERT) (Codd et al.,
1995; Barann et al., 2015). The effects of opioids on noradren-
aline and 5-HT transport have previously been studied using
rat brain synaptosomes (Larsen and Hyttel, 1985; Driessen
et al., 1993; Codd et al., 1995; Frink et al., 1996; Giusti et al.,
1997; Tzschentke et al., 2007). However, only one study of
which we are aware assessed a larger group of opioids using
the same rat transporter assay (Codd et al., 1995). Addition-
ally, no data have been reported on the effects of different
clinically used opioids on the human SERT, NET and
dopamine transporter (DAT) using the same method,
thus hindering direct comparisons of their transporter
inhibition potencies. Only one recent study assessed the
effects of a few opioids on the human SERT and showed
SERT inhibition by tramadol and pethidine but not
morphine, hydromorphone, fentanyl and alfentanil
(Barann et al., 2015). More information on the non-opioid
effects of various opioids is needed because these analgesic
substances are very widely used. Dopamine and the
DAT are involved in addiction. Inhibition of NET may
contribute to the analgesic effects of synthetic opioids,
such as the newly marketed dual-mechanism analgesic
tapentadol (Tzschentke et al., 2007; Bee et al., 2011;
Schroder et al., 2011). SERT inhibition may have analgesic
effects but may also increase the risk of 5-HT toxicity
(Boyer and Shannon, 2005). The adverse effects of 5-HT
can be mild and include nausea, vomiting and insomnia.
However, a more severe manifestation of 5-HT toxicity is
the potentially fatal serotonin syndrome, which includes
a triad of effects: mental state changes (delirium, agitation,
confusion and coma), autonomic stimulation (hyperther-
mia, tachycardia and diaphoresis) and neuromuscular
excitation (tremor, hyperreﬂexia and rigidity; Gillman,
2005). The serotonin syndrome has been associated with
several opioids or combinations of opioids with other
serotonergic drugs in numerous case reports (Schwartz
et al., 2008; Guo et al., 2009; Monte et al., 2010; Rastogi
et al., 2011; Walter et al., 2012; Shakoor et al., 2014; Abadie
et al., 2015). In a small analysis of pharmacovigilance data
from a single country, tramadol was the opioid that was
most frequently associated with the serotonin syndrome
(Chassot et al., 2012). However, a larger and more represen-
tative analysis of such spontaneous adverse-effect reporting
data is needed.
The primary aim of the present study was to investigate
and compare the potencies of a larger group of representative
and widely used opioids to inhibit the human SERT, NET and
DAT in vitro. We also tested whether opioids that interact with
one of these monoamine transporters induce transporter-
mediated monoamine release. Furthermore, activity at
5-HT1A, 5-HT2A and 5-HT2C receptors may be involved in
animal models of the serotonin syndrome (Martin et al.,
1991; Van Oekelen et al., 2002; Tao et al., 2003; Fox et al.,
2009). Therefore, we determined the afﬁnities of opioids to
bind directly to these 5-HT receptors. Finally, we collected
data on the frequency of reports of 5-HT toxicity associated
with opioids and sought to establish links between the
in vitro data and clinical data.
Methods
Inhibition of 5-HT, dopamine and
noradrenaline uptake
Inhibition of the human NET, DAT and SERT was assessed in
HEK 293 cells (Invitrogen, Zug, Switzerland) stably
transfected with the respective human transporter as previ-
ously described (Tatsumi et al., 1997; Hysek et al., 2012;
Luethi et al., 2017b). The cells were cultured in DMEM
(Gibco, Life Technologies, Zug, Switzerland) with 10% fetal
bovine serum (Gibco) and 250 μg·mL1 Geneticin (Gibco)
to 70–90% conﬂuence, detached and then resuspended
(3 × 106 cells·mL1) in Krebs-Ringer bicarbonate buffer
(Sigma-Aldrich, Buchs, Switzerland). For [3H]-dopamine
uptake experiments, the uptake buffer was supplemented
with 0.2 mg·mL1 ascorbic acid. The cell suspension
(100 μL) was incubated with 25 μL buffer containing the test
drugs, vehicle control or monoamine-speciﬁc inhibitors
(10 μM nisoxetine for NET, 10 μMmazindol for DAT and
10 μM ﬂuoxetine for SERT) for 10 min in a round bottom
96-well plate at room temperature by shaking at 450
rotations min1 on a rotary shaker. Monoamine uptake
transport was then initiated by adding 50 μL of [3H]-
noradrenaline (13.1 Ci·mmol1; PerkinElmer), [3H]-
dopamine (30.0 Ci·mmol1, PerkinElmer) or [3H]-5-HT
(80.0 Ci·mmol1; Anawa, Zurich, Switzerland) dissolved in
buffer at a ﬁnal concentration of 5 nM for an additional
10 min. Thereafter, 100 μL of the cell suspension was trans-
ferred to 500 μL microcentrifuge tubes that contained 50 μL
of 3 M KOH and 200 μL silicon oil (1:1 mixture of silicon oil
types AR 20 and AR 200; Sigma-Aldrich). To separate the cells
from the uptake buffer, they were centrifuged through silicone
oil for 3 min at 16 550 × g, and the tubes were frozen in liquid
nitrogen immediately afterward. The cell pellet was then cut
into 6 mL scintillation vials (Perkin-Elmer) that contained
0.5 mL lysis buffer (0.05 M TRIS–HCl, 50 mM NaCl, 5 mM
EDTA and 1% NP-40 in water). The samples were shaken for
1 h before 5 mL scintillation ﬂuid (Ultimagold, Perkin Elmer,
Schwerzenbach, Switzerland) was added. Monoamine uptake
was then quantiﬁed by liquid scintillation counting on a
Packard 1900 TR Tri-Carb Liquid Scintillation Counter
(Packard Instrument Company). Non-speciﬁc uptake that
was determined in the presence of selective inhibitors
was subtracted from the total counts, and monoamine uptake
was compared with the vehicle control.
Transporter-mediated monoamine release
Substances that inhibit the monoamine uptake may also be
monoamine transporter substrates and release monoamines
via the transporter. The potential of the drugs which
inhibited the uptake to also initiate transporter-mediated
noradrenaline or 5-HT efﬂux was assessed in HEK 293 cells
that overexpressed the respective human transporter as previ-
ously described (Simmler et al., 2013, 2014; Luethi et al.,
2017b). Brieﬂy, 100 000 cells per well were cultured overnight
in a poly-D-lysine coated XF24 cell culture microplate
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(Seahorse Biosciences, North Billerica, MA, USA). Thereafter,
the cells were preloaded with 10 nM [3H]-noradrenaline,
[3H]-dopamine or [3H]-5-HT diluted in 85 μL Krebs-HEPES
buffer (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM
MgSO4, 1.2 mM KH2PO4, 10 mM HEPES, 10 mM D-glucose,
pH 7.5) containing 10 μM pargyline and 0.2 mg·mL1
ascorbic acid for 20 min at 37°C, washed twice and treated
with 1000 μL Krebs-HEPES buffer containing 100 μM of the
test drugs for 15 min (DAT and SERT) or 45 min (NET) at
37°C by shaking at 300 rotations min1 on a rotary shaker.
The cells were then washed again with cold buffer and lysed
in 50 μL lysis buffer during 1 h. Thereafter, 40 μL of the cell
lysate was transferred into 4 mL scintillation vials with
3.5 mL scintillation ﬂuid, and the radioactivity inside the
cells was quantiﬁed by liquid scintillation counting as
described for the monoamine uptake inhibition assay.
Monoamine transporter blockers (10 μM nisoxetine for
NET, 10 μM mazindol for DAT and 10 μM citalopram for
SERT) were included in the experiment to determine
‘pseudo-efﬂux’ caused by non-speciﬁc monoamine release
and subsequent reuptake inhibition (Scholze et al., 2000).
Thus, these uptake inhibitors served as negative control
conditions. 3,4-Methylenedioxymethamphetamine
(MDMA) was used as comparator compound that is known
to induce monoamine release in this assay (positive control
in each experiment; Hysek et al., 2012; Simmler et al., 2014).
All of the conditions were normalized to radioactive counts
of the assay buffer control condition. The use of a single high
concentration and the release durations were based on
kinetic evaluation of the release-over-time curves for
substrate-releasers in previous studies (Hysek et al., 2012;
Simmler et al., 2014).
5-HT1A and 5-HT2A receptor radioligand
binding assays
For membrane preparations, HEK293 cells, transiently
transfected with the 5-HT1A or 5-HT2A receptor, were released
from culture ﬂasks using trypsin/EDTA, harvested, washed
twice with ice-cold PBS (without Ca2+ and Mg2+), pelleted at
210 × g for 5 min at 4°C, frozen and stored at 80°C (Luethi
et al., 2017a). Frozen pellets were suspended in 20 mL
HEPES-NaOH (20 mM, pH 7.4) containing 10 mM EDTA
and homogenized with a Polytron (PT 6000, Kinematica, Lu-
cerne, Switzerland) at 14 000 rpm for 20 s. The homogenates
were centrifuged at 48 000 × g for 30 min at 4°C. Subse-
quently, the supernatants were removed and discarded, and
the pellets resuspended in 20 mL HEPES-NaOH (20 mM,
pH 7.4) containing 0.1 mM EDTA using the Polytron (20 s
at 14 000 rpm). This procedure was repeated and the ﬁnal pel-
lets resuspended in HEPES-NaOH containing 0.1 mM EDTA
and homogenized using the Polytron. Typically, aliquots of
2 mL membrane portions were stored at 80°C. With
each new membrane batch, the KD was determined by a satu-
ration curve.
For the competitive binding assays, 1.39 nM [3H]8-
hydroxy-2-(di-n-propylamine)tetralin ([3H]-8-OH-
DPAT) and 0.45 nM [3H]-ketanserin were used as
5-HT1A and 5-HT2A receptor radioligands, respectively,
at concentrations equal or close to the KD values
(1 and 0.45 nM, respectively). Speciﬁc binding of the
radioligands to the target receptors was deﬁned as the
difference between total binding (binding buffer alone)
and non-speciﬁc binding determined in the presence of
10 μM pindolol (for the 5-HT1A receptor radioligand) or
10 μM spiperone (for the 5-HT2A receptor radioligand).
The compounds were tested at a broad range of con-
centrations (30 pM to 30 μM) in duplicates. The test
compounds were diluted in binding assay buffer at
pH 7.4 (50 mM Tris/HCl, 10 mM MgCl2 and 1 mM EGTA),
and dilution curves were made in assay microplates
(Greiner, 96 well, U-bottom, PS). A total of 50 μL of
radioligand and 100 μL of membrane suspension were
added to the assay plates (ﬁnal volume in each well,
200 μL) that were incubated and shaken for 30 min at
room temperature. Incubations were terminated by rapid
ﬁltration through Uniﬁlter-96 plates (Packard Instrument
Company, PerkinElmer, Schwerzenbach, Switzerland)
and glass ﬁlters GF/C (PerkinElmer) presoaked for a
minimum of 1 h in polyethylenimine (0.3%) and washed
three times with ice-cold washing buffer (50 mM
Tris/HCl, pH 7.4). After the addition of Microscint 40
(45 μL per well, PerkinElmer), the Uniﬁlter-96 plates were
sealed. After 1 h, radioactivity was counted using a
TopCount Microplate Scintillation Counter (Packard
Instrument Company).
5-HT2C receptor radioligand binding assay
Substances that showed binding at the 5-HT1A and 5-HT2A
receptors were also tested at the 5-HT2C receptor (many com-
pounds that bind to the 5-HT2A receptor also bind to the
5-HT2C receptor). For membrane preparations, HEK293 cells,
transiently transfected with the 5-HT2C receptor, were re-
leased from culture ﬂasks using trypsin/EDTA, harvested,
washed twice with ice-cold PBS (without Ca2+ and Mg2+),
pelleted at 210 × g for 5 min at 4°C, frozen and stored at
80°C (Luethi et al., 2017a). Frozen pellets were suspended
in 20 mL HEPES/NaOH (20 mM, pH 7.4) containing 10 mM
EDTA and homogenized with a Polytron (PT 6000,
Kinematica, Lucerne, Switzerland) at 14 000 rpm for 20 s.
The homogenates were centrifuged at 48 000 × g for 30 min
at 4°C. Subsequently, the supernatants were removed and
discarded, and the pellets resuspended in 20 mL HEPES-
NaOH (20 mM, pH 7.4) containing 0.1 mM EDTA using the
Polytron (20 s at 210 × g). This procedure was repeated and
the ﬁnal pellets resuspended in HEPES/NaOH containing
0.1 mM EDTA and homogenized using the Polytron. Typi-
cally, aliquots of 2 mL membrane portions were stored at
80°C. With each new membrane batch, the KD was deter-
mined by a saturation curve.
For the competitive binding assay, [3H]-mesulergine
was used as 5-HT2C receptor radioligand at 1.6 nM, a concen-
tration equal to the KD value. Speciﬁc binding of the
radioligand to the target receptor was deﬁned as the differ-
ence between total binding (binding buffer alone) and non-
speciﬁc binding determined in the presence of 10 μM
mianserin. The compounds were tested at a broad range of
concentrations (30 pM to 30 μM) in duplicates. The test com-
pounds were diluted in binding assay buffer at pH 7.4 (50mM
Tris/HCl, 10 mM MgCl2, 1 mM EGTA and 10 μM pargyline),
and dilution curves were made in 96-well white polystyrene
assay plates (Sigma-Aldrich, Buchs, Switzerland). Membrane
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stocks were thawed and resuspended to a concentration of
approximately 0.04 mg protein mL1 binding assay buffer
using a Polytron tissue homogenizer. The membrane homog-
enate (40 μg·mL1) was then lightly mixed for 5–30 min with
YSi-poly-l-lysine (PerkinElmer, Schwerzenbach, Switzerland)
at 0.5 mg beads per well. A total of 50 μL of the
membranes/beads mixture was added to each well of the
assay plate that contained the radioligand (50 μL) and the test
compounds (ﬁnal volume in each well, 200 μL) to start the
assay. The assay plates were sealed, incubated for 2 h at room
temperature with agitation and then counted in the PVT
SPA counting mode of a TopCount Microplate Scintillation
Counter (Packard Instrument Company, PerkinElmer,
Schwerzenbach, Switzerland).
Cytotoxicity
To conﬁrm cell integrity during the pharmacological assays,
cytotoxicity was assessed using the ToxiLight bioassay
(Lonza, Basel, Switzerland) according to the manufacturer’s
instructions and as described previously (Rickli et al., 2015).
The assay quantitatively measures the release of adenylate
kinase from damaged cells, providing a highly sensitive
method of measuring cytolysis (Crouch et al., 1993).
Database searches for opioids associated with
serotonin syndrome
The Medline PubMed database and VigiBase™ World Health
Organization (WHO) Global Database of Individual Case
Safety Reports (ICSRs) were searched using VigiLyze™ as the
search tool for cases of serotonin syndrome associated with
opioids. Published cases and case series of serotonin syn-
drome were searched in Medline using the terms ‘serotonin
syndrome’ AND each of the opioids investigated in the pres-
ent study in vitro. All publications up to 31 August 2016 were
included. The reports were manually searched for relevance,
and the drugs were classiﬁed as ‘suspected among other
drugs’ or ‘the only suspected drug’ (according to the assess-
ment of the authors of the case reports). Review articles that
did not report actual patient data were not considered.
The WHO database search was performed on 18 April
2016. For each opioid, we identiﬁed all spontaneous reports
and ﬁltered the results using the Medical Dictionary for Regu-
latory Activities (MedDRA) adverse reaction term ‘serotonin
syndrome’. Only ICSRs in which the opioid was reported as
‘suspected’ or ‘interacting’were included. ICSRs that reported
that the opioid were ‘concomitantly’ used but without a time
relationship with the adverse reaction were excluded.
Data and statistical analysis
The data and statistical analysis complied with the recom-
mendations on experimental design and analysis in pharma-
cology (Curtis et al., 2015). Calculations were performed
using Prism 7.0a software (GraphPad, San Diego, CA, USA).
Monoamine transporter inhibition data were ﬁt by nonlinear
regression to variable-slope sigmoidal dose–response curves,
and IC50 values were determined. The SERT/NET ratio is
expressed as (1/SERT IC50):(1/NET IC50). Compound-induced
release from ﬁve independent experiments was compared
with negative controls using ANOVA followed by Dunnett’s
test. Values of P < 0.05 were considered statistically
signiﬁcant. The substances were considered a monoamine
releaser if they caused signiﬁcantly higher efﬂux than the
negative controls. IC50 values of radioligand binding were
determined by calculating nonlinear regression curves for
a one-site model using three independent 10-point
concentration–response curves, run in duplicate, for
each compound. Ki (afﬁnity) values, which correspond to
the KDs, were determined using the Cheng-Prusoff equation:
Ki = IC50 / (1 + [S]/KM). Ki values are presented as means ± SD
(in μM).
Materials
Buprenorphine, citalopram, codeine, dextro-
methorphan, dihydrocodeine, fentanyl, heroin
(diacetylmorphine, diamorphine), 6-acetylmorphine
(6-mono-acetylmorphine), hydrocodone, hydro-
morphone, mazindol, MDMA, methadone, morphine,
oxycodone, oxymorphone, pethidine (meperidine),
tramadol, O-desmethyl-cis-tramadol, tapentadol,
venlafaxine and ﬂuoxetinewere purchased from Lipomed
(Arlesheim, Switzerland). Mianserin, nisoxetine, pargyline,
pindolol and spiperone were supplied by Sigma-Aldrich
(Buchs, Switzerland). D(S)-methadone and l(R)-metha-
done were obtained from Alsachim (Illkirch Graffenstaden,
France). The HPLC purity of all of the substances was >98%.
[3H]-8-OH-DPAT, [3H]-ketanserin and [3H]-mesulergine were
supplied by Perkin-Elmer.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetophar-
macology.org, the common portal for data from the
IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al.,
2016), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b).
Results
Inhibition of 5-HT, dopamine and
noradrenaline uptake
IC50 values for SERT, DAT and NET inhibition are shown in
Table 1, and the full inhibition curves are shown in
Supporting Information Figure S1. Dextromethorphan, l(R)-
methadone and racemic methadone potently inhibited the
SERT, with concentrations that are likely to be reached in
the human brain when these drugs are used in patients
(Table 3). Dextromethorphan was as potent as ﬂuoxetine.
Pethidine, tramadol, tapentadol and d(S)-methadone also
inhibited the SERT at low micromolar concentrations, with
IC50 values of 1–10 μM (Table 1) and at concentrations similar
to or close to those reached in human brain at therapeutic
doses (Table 3). The SERT inhibition potency and SERT/NET
ratio values of tramadol and tapentadol were in the same
order of magnitude (Table 1).
Tapentadol was the most potent NET inhibitor, which
was almost as potent as venlafaxine (Table 1). Pethidine,
tramadol, l(R)-methadone, methadone, dextromethorphan
and O-desmethyltramadol also inhibited the NET at low
micromolar concentrations (1–10 μM; Table 1). Typical
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phenanthrene opioids, including 6-acetylmorphine,
buprenorphine, codeine, dihydrocodeine, heroin,
hydrocodone, hydromorphone, morphine, oxycodone and
oxymorphone, did not inhibit the SERT or NET (all IC50
values >100 μM). None of the opioids tested inhibited the
DAT (all IC50 values ≥60 μM).
Transporter-mediated release of 5-HTand
noradrenaline
Opioids that inhibited monoamine uptake were also tested
with regard to transporter-mediated monoamine release.
None of the opioids acted as a releaser of 5-HT or noradrena-
line at a high concentration of 100 μM (Supporting Informa-
tion Figure S2). Only the positive control MDMA induced
signiﬁcantly greater 5-HT and noradrenaline release than
citalopram and nisoxetine respectively. Dopamine release
was not assessed because none of the opioids interacted with
the DAT in the uptake assay.
5-HT1A, 5-HT2A and 5-HT2C receptor binding
affinity
None of the opioids exhibited relevant afﬁnity for the 5-HT1A re-
ceptor (Ki > 17 μM) with the exception of fentanyl (Table 1). In
contrast, methadone, pethidine and fentanyl showed afﬁnity
for the 5-HT2A receptor at low micromolar concentrations
(Table 1) that were in the range of those concentrations ob-
served in plasma or estimated to be present in the brain in
humans treated therapeutically with methadone (Table 3).
Methadone but none of the other opioids also showed very
low afﬁnity for the 5-HT2C receptor (Table 1).
Cytotoxicity
None of the opioids showed cytotoxicity.
Opioids associated with the serotonin syndrome
The PubMed search yielded 99 patient cases (Supporting
Information Table S1) that involved 114 administrations of
opioids (Table 2). Twelve cases involved two opioids, and
three cases involved three opioids. In the few cases providing
detailed diagnostic information, serotonin syndrome was
typically diagnosed according to the criteria of Hunter
(Dunkley et al., 2003) or Sternbach (Sternbach, 1991). The
opioids that were most frequently reported to be associated
with serotonin syndrome (>10 cases) were fentanyl and
tramadol, followed by oxycodone and dextromethorphan
(Table 2). However, ﬁve of these cases involved both fentanyl
and oxycodone. All of the cases, with the exception of one
case that was associated with tramadol overdose (Marechal
et al., 2011) and one case that was associated with therapeutic
doses of dextromethorphan (Kinoshita et al., 2011), involved
other drugs in addition to the opioid. In most cases, SERT
inhibitors (SSRIs) were also involved, leading to serotonergic
toxicity usually shortly after dose escalation or the addition
of another serotonergic medication. SSRIs inhibited the SERT
Table 2
Cases of serotonin syndrome reported, classiﬁed by opioid associated with report
Drug
WHO database Medline database
Only suspected cause
or among others
Only suspected
cause
Number of published
cases
Opioid
Tramadol 647 62 26
Tapentadol 115 42 1
Fentanyl 363 19 45
Dextromethorphan 86 7 12
Pethidine 66 6 5
Hydromorphone 41 3 2
Buprenorphine 20 3 1
Oxycodone 101 2 13
Methadone 93 2 3
Morphine 64 1 4
Codeine 32 0 0
Hydrocodone 6 0 2
Dihydrocodeine 4 0 0
Oxymorphone 3 0 0
Serotonergic drugs for the treatment of depression
Fluoxetine 641 181 54
Citalopram 777 178 57
Duloxetine 993 550 20
Venlafaxine 859 240 75
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more potently than the opioids as shown for some examples
in Table 1. These SSRIs were also frequently reported (>10
cases/drug) as potential causes of clinical serotonin syndrome
cases (Table 2).
The WHO database search yielded a total of 1641 ICSRs
with at least one of the opioids noted as the suspected drug
or an interacting drug and 147 ICSRs with the opioid as the
only suspected cause (Table 2). The opioids that were most
frequently reported in association with serotonin syndrome
either alone or in combination with other drugs (e.g. SSRIs)
were tramadol, fentanyl, tapentadol, oxycodone, methadone
and dextromethorphan (Figure 1, Table 2). The single
suspected opioids that were most frequently linked to seroto-
nin syndrome were (in decreasing order) tramadol,
tapentadol, fentanyl, dextromethorphan and pethidine
(Table 2). In the majority of cases, serotonin syndrome oc-
curred within the labelled dose range with overdose reported
in less than 10% of the cases. Serotonergic drugs for the
treatment of depression were reported to be suspected or
interacting drugs in the majority of these ICSRs involving
opioids. As expected, a separate WHO database search
showed that the serotonergic drugs for the treatment of
depression were also frequently reported as suspected or
interacting drugs associated with serotonin syndrome
(positive control, Table 2).
Discussion
The present in vitro study showed that the synthetic atypical
opioids dextromethorphan, methadone, pethidine, tramadol
and tapentadol acted as SERT and NET inhibitors at or close to
clinically observed free drug plasma and estimated free
human brain concentrations (Table 3). Dextromethorphan
preferentially inhibited the SERT versus NET. Tapentadol
and tramadol were 2.6- and 1.6-fold more potent inhibitors
of the NET versus SERT respectively. Consistent with the
present ﬁndings, tramadol and pethidine inhibited the hu-
man SERT in vitro, whereas morphine, hydromorphone and
fentanyl were inactive (Barann et al., 2015). Also consistent
with the present ﬁndings, dextromethorphan, methadone,
pethidine, tramadol and tapentadol have previously been
shown to block the rat SERT and NET in rat brain synapto-
some in vitro assays (Larsen and Hyttel, 1985; Driessen et al.,
1993; Codd et al., 1995; Frink et al., 1996; Giusti et al., 1997;
Tzschentke et al., 2007). Morphine and codeine did not block
the rat SERT or NET (Codd et al., 1995; Frink et al., 1996;
Tzschentke et al., 2007) as shown here for the human trans-
porter. In rats, both tramadol and tapentadol increased extra-
cellular 5-HT and noradrenaline levels in the brain, measured
by in vivomicrodialysis (Tzschentke et al., 2007; Bloms-Funke
et al., 2011).
The assumption that formed the basis of the present study
was that opioids may increase the risk of serotonergic toxicity
by inhibiting the SERT similarly to antidepressants and
possibly at higher concentrations. In fact, SERT inhibition
in vitro was found at opioid concentrations that were similar
to those observed in vivo in human plasma and estimated to
be present in the brain when the respective opioids were used
clinically (Table 3).
We also found that opioids that were SERT inhibitors
in vitro were also among those that were most frequently
reported to be associated with serotonin syndrome in
patients, including tramadol, tapentadol, methadone and
dextromethorphan. However, fentanyl and oxycodone were
also linked to serotonin syndrome but did not interact with
Figure 1
Number of spontaneous ICSR of serotonin syndrome in the VigiBase™WHO Global Database per opioid reported as the suspected cause among
other drugs or the only suspected cause.
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the SERT in vitro, suggesting SERT-independent effects on the
5-HT system in vivo. Therefore, some opioids may also
directly interact with 5-HT receptors, such as 5-HT1A and
5-HT2A, that have been implicated in animal models of sero-
tonin syndrome (Martin et al., 1991; Van Oekelen et al.,
2002; Tao et al., 2003; Fox et al., 2009), or indirectly activate
5-HT release via opioid receptor stimulation (Tao and
Auerbach, 1995; Tao and Auerbach, 2002; Benade et al.,
2017). In fact, the present study showed that fentanyl
directly bound to 5-HT1A, as previously shown (Martin
et al., 1991) and, also to 5-HT2A receptors, although both at
concentrations clearly higher than those observed in human
plasma. Methadone and pethidine also showed relevant
afﬁnity for the 5-HT2A receptor at or near human plasma con-
centrations during therapeutic use of these opioids (Table 3).
Tramadol was also reported to induce 5-HT efﬂux in the rat ra-
phe nucleus, possibly independently from its action as a SERT
inhibitor (Bamigbade et al., 1997). None of the opioids that
were tested in the present study was a DAT inhibitor, consis-
tent with previous studies of the rat DAT (Frink et al., 1996).
Thus, unlike amphetamines and cocaine that inhibited the
DAT in the assay used in the present study (Simmler et al.,
2013, 2014), opioids indirectly stimulate the dopaminergic
system in vivo (Benade et al., 2017), which is the basis for their
reinforcing properties.
Drugs that inhibit the NET have analgesic properties
when administered alone but also potentiate opioid-induced
analgesia (Luccarini et al., 2004; Hall et al., 2011). While
opioids primarily produce their analgesic effects via μ-opioid
receptor stimulation, noradrenergic systems may also be
critically involved in the analgesic properties of some com-
pounds (Sawynok and Reid, 1987; Schroder et al., 2010,
2011; Benade et al., 2017). NET knockout did not signiﬁcantly
alter morphine-induced analgesia in mice indicating no
major role of the NET in the analgesic response to morphine
(Hall et al., 2011), which showed no NET inhibition in the
present study. However, noradrenaline clearly contributes to
the analgesic effects of tapentadol, in addition to its
opioidergic properties (Tzschentke et al., 2007; Bee et al.,
2011; Schroder et al., 2011). In the present study, tapentadol
was the most potent human NET inhibitor among all of the
opioids tested. Tapentadol also inhibited noradrenaline
uptake into rat synaptosomes and increased extracellular
brain concentrations of noradrenaline (Tzschentke et al.,
2007; Benade et al., 2017). In the present study, tapentadol
inhibited the human NET approximately threefold more
potently than the human SERT, conﬁrming data from a study
of rat transporters (Tzschentke et al., 2007). Apart from
tapentadol, tramadol was the only other opioid that more
potently inhibited the NET versus SERT, although it was
almost equipotent at these two transporters. Additionally,
the SERT/NET ratio did not differ relevantly between
tapentadol and tramadol, indicating that there may not be a
robust or large difference between the two compounds in
terms of NET or SERT inhibition. Finally, the present study
showed that pethidine, tramadol and l(R) methadone also
inhibited the NET at concentrations within or close to the
range that is present in human plasma and brain (Table 3).
Thus, noradrenaline may contribute to the analgesic effects
not only of tapentadol but also of pethidine, tramadol and
l(R)-methadone.
The present clinical data analysis showed that serotoner-
gic drugs for the treatment of depression were also involved
in the majority of serotonin syndrome cases associated
with opioids. In another analysis, most cases of serotonin
syndrome resulted from the combined use of more than
one serotonergic drug (Chassot et al., 2012) indicating a
higher risk of serotonin syndrome when opioids are used
with other serotonergic substances. The combined use of
opioid analgesics with serotonergic antidepressants is very
common in the treatment of chronic pain. For example, in
a recent analysis among 433 multimorbid hospital patients
with chronic pain, 71% of the patients received opioids and
35% received antidepressants and potential interactions
between opioids and serotonergic antidepressants (SSRIs,
SNRIs) were identiﬁed in 57 (13%) of all patients
(Siebenhuener et al., 2017).
The present study has important limitations. The WHO
data may mainly reﬂect the frequency of reporting rather
than the true incidence of serotonin syndrome per opioid.
Underreporting is common, and the true incidence of
serotonin syndrome cannot be estimated from the present
data. Additionally, we did not account for differences in the
prescribing frequency or time on market. Adverse effects
may be more frequently reported in the case of a novel
medication. For example, tramadol and tapentadol were ﬁrst
reported in 1997 and 2010 respectively. Additionally, most
cases were reported during the last 10 years, possibly
reﬂecting changes in reporting and/or potential bias that
resulted from post-marketing studies of more recently
marketed opioids. Furthermore, the diagnosis of serotonin
syndrome may not be correct in some cases or is at least often
not well documented in many spontaneous reports. There
was no qualitative analysis of the reported cases, and some
were only poorly documented, and some symptoms could
have been other adverse effects of the opioids not meeting
all the criteria of serotonin syndrome. Additionally, the
reported associations are possible or likely but not deﬁnitive.
In the majority of the reports of serotonin syndrome, opioids
were co-used with other substances and they were infre-
quently noted as the only suspected cause. The present
spontaneous report data can only generate signals of possible
adverse reactions that need further observation but cannot be
used as prevalence markers or conﬁrmation of a causal
relationship. Nevertheless, the opioids that were more
frequently reported to be associated with serotonin
syndrome in the WHO database were generally the same
opioids that were more frequently mentioned in case reports
in PubMed.
In conclusion, we have characterized the effects of a series
of opioids on the human SERT, NET, DAT, 5-HT1A and 5-HT2A
receptors using the same method, thus allowing direct
comparisons between substances. Several synthetic opioids
inhibited the NET and SERT, which may contribute to
their analgesic properties but may also increase the risk of
5-HT toxicity. Serotonin syndrome may result from
SERT inhibition by tramadol, tapentadol, methadone, dex-
tromethorphan and pethidine, especially when combined
with other serotonergic medications, but there may also be
SERT-independent effects with other opioids, such as fenta-
nyl and oxycodone. Thesemechanisms and the risk of seroto-
nin syndrome need to be further investigated.
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Figure S1 Monoamine uptake inhibition in stably
transfected HEK 293 cells that expressed the human NET,
DAT, or SERT. The data are presented as the mean ± SEM of
three independent experiments. Curves were ﬁtted by non-
linear regression, and corresponding IC50 values are shown
in Table 1. DAT inhibition curves were not performed for sub-
stances that did not inhibit the DAT at 100 μM.
Figure S2 None of the opioids released serotonin (5-HT) or
norepinephrine (NE). Monoamine release was induced by
100 μMof the compounds after preloading HEK 293 cells that
expressed the human NET or SERT with radiolabeled mono-
amine. The dashed line marks nonspeciﬁc ‘pseudo-efﬂux’
that arises from monoamine diffusion and subsequent reup-
take inhibition. Substances that caused signiﬁcantly more
monoamine efﬂux (***P < 0.001) than non-releasing uptake
inhibitors (open bars) were determined to be monoamine
releasers. 3,4-Methylenedioxymethamphetamine (MDMA)
served as positive control known to release 5-HT and NE.
There was a signiﬁcant main effect of 5-HT and NE release
(F9,64 = 89.13, P < 0.001 and F10,78 = 21.46, P < 0.001, re-
spectively) but only the positive control MDMA induced sig-
niﬁcantly greater 5-HT and NE release compared with
citalopram and nisoxetine (both P < 0.001) respectively.
The data are presented as the mean and SEM of ﬁve indepen-
dent experiments.
Table S1 Cases of opioid-associated serotonin syndrome re-
ported by PubMed.
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